Huizenga Theodore Alan, SVP, CAO, reported an open-market or private sale at Ultragenyx Pharmaceutical Inc. involving 161.000000 shares for an estimated $2252.39. Reported holdings after the transaction were 69146.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
Form 4 relationship flags and nearby filing context
SVP, Chief Accounting Officer
Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
Includes 396 shares acquired under the Company's Amended and Restated Employee Stock Purchase Place on April 30, 2026.
Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
0 other filings
0 recent txs